Literature DB >> 18798334

Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C.

Marija Zeremski1, Lydia M Petrovic, Luis Chiriboga, Queenie B Brown, Herman T Yee, Milan Kinkhabwala, Ira M Jacobson, Rositsa Dimova, Marianthi Markatou, Andrew H Talal.   

Abstract

UNLABELLED: Chemokines, chemotactic cytokines, may promote hepatic inflammation in chronic hepatitis C virus (HCV) infection through the recruitment of lymphocytes to the liver parenchyma. We evaluated the association between inflammation and fibrosis and CXCR3-associated chemokines, interferon-gamma (IFN-gamma)-inducible protein 10 (IP-10/CXCL10), monokine induced by IFN-gamma (Mig/CXCL9), and interferon-inducible T cell alpha chemoattractant (I-TAC/CXCL11), in HCV infection. Intrahepatic mRNA expression of these chemokines was analyzed in 106 chronic HCV-infected patients by real-time PCR. The intrahepatic localization of chemokine producer cells and CXCR3(+) lymphocytes was determined in selected patients by immunohistochemistry. We found elevated intrahepatic mRNA expression of all three chemokines, most markedly CXCL10, in chronic HCV-infected patients with higher necroinflammation and fibrosis. By multivariable multivariate analysis, intrahepatic CXCL10 mRNA expression levels were significantly associated with lobular necroinflammatory grade and HCV genotype 1. In the lobular region, CXCL10-expressing and CXCL9-expressing hepatocytes predominated in areas with necroinflammation. Strong CXCL11 expression was observed in almost all portal tracts, whereas CXCL9 expression varied considerably among portal tracts in the same individual. Most intrahepatic lymphocytes express the CXCR3 receptor, and the number of CXCR3(+) lymphocytes was increased in patients with advanced necroinflammation.
CONCLUSION: These findings suggest that the CXCR3-associated chemokines, particularly CXCL10, may play an important role in the development of necroinflammation and fibrosis in the liver parenchyma in chronic HCV infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18798334      PMCID: PMC2579317          DOI: 10.1002/hep.22500

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  23 in total

Review 1.  International union of pharmacology. XXII. Nomenclature for chemokine receptors.

Authors:  P M Murphy; M Baggiolini; I F Charo; C A Hébert; R Horuk; K Matsushima; L H Miller; J J Oppenheim; C A Power
Journal:  Pharmacol Rev       Date:  2000-03       Impact factor: 25.468

2.  Hepatic inflammation and immunity: a summary of a conference on the function of the immune system within the liver.

Authors:  P Bertolino; G Klimpel; S M Lemon
Journal:  Hepatology       Date:  2000-06       Impact factor: 17.425

Review 3.  The biology of chemokines and their receptors.

Authors:  D Rossi; A Zlotnik
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

4.  Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.

Authors:  M Diago; G Castellano; J García-Samaniego; C Pérez; I Fernández; M Romero; O L Iacono; C García-Monzón
Journal:  Gut       Date:  2005-09-08       Impact factor: 23.059

5.  DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection.

Authors:  C B Bigger; K M Brasky; R E Lanford
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

Authors:  T Poynard; V Ratziu; F Charlotte; Z Goodman; J McHutchison; J Albrecht
Journal:  J Hepatol       Date:  2001-05       Impact factor: 25.083

7.  Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.

Authors:  Ana I Romero; Martin Lagging; Johan Westin; Amar P Dhillon; Lynn B Dustin; Jean-Michel Pawlotsky; Avidan U Neumann; Carlo Ferrari; Gabriele Missale; Bart L Haagmans; Solko W Schalm; Stefan Zeuzem; Francesco Negro; Elke Verheij-Hart; Kristoffer Hellstrand
Journal:  J Infect Dis       Date:  2006-08-29       Impact factor: 5.226

8.  Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C.

Authors:  H Fontaine; B Nalpas; B Poulet; F Carnot; H Zylberberg; C Brechot; S Pol
Journal:  Hum Pathol       Date:  2001-09       Impact factor: 3.466

9.  Progression of fibrosis in untreated patients with hepatitis C virus infection.

Authors:  L Martin Lagging; Johan Westin; Elisabeth Svensson; Nibia Aires; Amar P Dhillon; Magnus Lindh; Rune Wejstål; Gunnar Norkrans
Journal:  Liver       Date:  2002-04

Review 10.  The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection.

Authors:  M Zeremski; L M Petrovic; A H Talal
Journal:  J Viral Hepat       Date:  2007-10       Impact factor: 3.728

View more
  96 in total

1.  Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients.

Authors:  S Johansson; W Talloen; M Tuefferd; J M Darling; A Scholliers; G Fanning; M W Fried; J Aerssens
Journal:  Aliment Pharmacol Ther       Date:  2015-08-28       Impact factor: 8.171

Review 2.  Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.

Authors:  Tzu-Hao Lee; Hans L Tillmann; Keyur Patel
Journal:  Mol Diagn Ther       Date:  2014-02       Impact factor: 4.074

3.  Chemokine antagonism in chronic hepatitis C virus infection.

Authors:  Edgar D Charles; Lynn B Dustin
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

Review 4.  Lessons from rare tumors: hepatic lymphoepithelioma-like carcinomas.

Authors:  Antonio Solinas; Diego F Calvisi
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

5.  Pegylated interferon α-2b up-regulates specific CD8+ T cells in patients with chronic hepatitis B.

Authors:  Ji Chen; Yan Wang; Xue-Jie Wu; Jun Li; Feng-Qin Hou; Gui-Qiang Wang
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

6.  Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV.

Authors:  Armanda Casrouge; Jérémie Decalf; Mina Ahloulay; Cyril Lababidi; Hala Mansour; Anaïs Vallet-Pichard; Vincent Mallet; Estelle Mottez; James Mapes; Arnaud Fontanet; Stanislas Pol; Matthew L Albert
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

Review 7.  Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells.

Authors:  Barbara Rehermann
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

8.  Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection.

Authors:  Jason Grebely; Jordan J Feld; Tanya Applegate; Gail V Matthews; Margaret Hellard; Alana Sherker; Kathy Petoumenos; Geng Zang; Ineke Shaw; Barbara Yeung; Jacob George; Suzy Teutsch; John M Kaldor; Vera Cherepanov; Julie Bruneau; Naglaa H Shoukry; Andrew R Lloyd; Gregory J Dore
Journal:  Hepatology       Date:  2013-05-08       Impact factor: 17.425

Review 9.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

10.  Telaprevir-based treatment effects on hepatitis C virus in liver and blood.

Authors:  Andrew H Talal; Rositsa B Dimova; Eileen Z Zhang; Min Jiang; Marina S Penney; James C Sullivan; Martyn C Botfield; Ananthsrinivas Chakilam; Rishikesh Sawant; Christine M Cervini; Marija Zeremski; Ira M Jacobson; Ann D Kwong
Journal:  Hepatology       Date:  2014-07-31       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.